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Abstract
Background: Treatment of patients with COVID-19 has included supportive care to mainly relief symptoms of the
disease. Although World Health Organization (WHO) has not recommended any effective treatments for COVID-19,
there are some reports about use of antiviral drugs. The aim of this study is to determine the effect of Arbidol (ARB)
on COVID-19 disease.
Methods: Using an open-label randomized controlled trial, we examined the efficacy of ARB in patients with
COVID-19 in a teaching hospital. One hundred eligible patients with diagnosis of COVID-19 were recruited in the
study and assigned randomly to two groups of either hydroxychloroquine followed by KALETRA (Lopinavir/
ritonavir) or hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical
improvement 7 days after admission. The criteria of improvement were relief of cough, dyspnea, and fever. Time to
relief from fever was also assessed across the two groups. Without any dropouts, 100 patients were entered into
the study for the final analysis at significance level of 0.05.
Results: The mean age of patients was 56.6 (17.8) years and 56.2 (14.8) years in ARB and KALETRA groups,
respectively. Majority of patients were male across two groups (66 and 54%). The duration of hospitalization in ARB
group was significantly less than KALETRA arm (7.2 versus 9.6 days; P = 0.02). Time to relief fever was almost similar
across two groups (2.7 versus 3.1 days in ARB and KALETRA arms, respectively). Peripheral oxygen saturation rate
was significantly different after 7 days of admission across two groups (94% versus 92% in ARB and KALETRA
groups respectively) (P = 0.02). Based on multiple linear regression analysis, IHD, Na level, and oxygen saturation at
the time of admission and type of therapy were the independent adjusted variables that determined the duration
of hospitalization in patients with COVID-19.
Conclusion: Our findings showed that Arbidol, compared to KALETRA, significantly contributes to clinical and
laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of
hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB against COVID-19 using
larger sample size and multicenter design.
Trial registration: IRCT20180725040596N2 on 18 April 2020.
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Background
Coronavirus disease (COVID-19) is an infectious dis-
ease caused by a new coronavirus named SARS-COV-2.
Majority of people infected by this virus will experience
mild to moderate symptoms of respiratory illness. This
virus can be transmitted by droplets when an infected
person sneezes or coughs [1].
Since first cases of COVOD-19 were reported in Decem-
ber 2019 fromWuhan in China, more than 42 million cases
of this disease have been reported globally leading to more
than 1,100,000 deaths [2]. COVID-19 has affected more
than 180 countries and the problem is going to be worse
due to there are no specific vaccines or treatments for
COVID-19. World Health Organization (WHO) declared
the outbreak of novel Corona virus a Public Health
Emergency of International Concern, or PHEIC on January
2020 [3].
This is a severe problem for public health because the
majority of infected people do not develop symptoms
but could transmit the disease to the others during the
incubation period [4].
There are currently no known effective therapy for
infection with SARS-COV-2. Treatment of moderate to
severe forms of COVID-19 treatment is generally neces-
sary. Treatment of patients with COVID-19 is mainly
supportive care to relief symptoms. Although WHO has
not recommended any effective treatments for COVID-
19, there are reports about the use of some antiviral
drugs (oseltamivir, lopinavir/ritonavir), antibiotics,
hydroxychloroquine and glucocorticoids for treatment in
this patient population [4]. However, there are many
ongoing clinical trials evaluating potential treatments for
COVID-19.
The other drugs also were recommended as a pos-
sible therapeutic options for the COVOD-19 such as
Remdesivir and Chloroquine phosphate [5, 6].
Recently Australian scientists have published a
research indicating that Ivermectin, an approved anti-
parasitic drug is highly effective against the COVID-19
virus when applied to an infected cell culture [7].
Arbidol (ARB) also known as Umifenovir is a Russian-
made drug using for some enveloped and non-enveloped vi-
ruses. ARB is well known in Russia and China, and with a
lesser extent in other countries but not in North America.
Arbidol has been used against influenza A and B viruses, and
recently against hepatitis C virus (HCV) [8, 9]. ARB can pre-
vent contact and penetration of virus to host cells via avoid-
ing the fusion of the virus lipid shell to the cell membrane. It
has been shown that ARB could inhibit COVID-19 infection
through interfering the release of SARS-CoV-2 from intra-
cellular vesicles [10].
At present, there is not any potent and specific
antiviral therapy or vaccine for SARS-COV-2. There-
fore developing an effective drug for therapy or
control of this disease is very critical option to
control the COVID-19 outbreak.
The aim of current study was to determine the efficacy
of ABD in treatment of COVID-19.
Methods
Design and participants
This open-label randomized controlled trial of efficacy
of ARB against COVID-19 was conducted between 20
April and 18 June 2020 in a teaching hospital in Iran
University of medical Sciences (IUMS) in Tehran,
Iran. The current clinical trial was done in accordance
with the principles of the Declaration of Helsinki and
the International Conference on Harmonization–Good
Clinical Practice guidelines. The study protocol was
approved by the ethics committee of Iran University of
Medical Sciences (IR.IUMS.RCT.1399.090) and regis-
tered in Iranian Registry of Clinical Trials (IRCT) with
register number of IRCT20180725040596N2 on 18
April 2020 (URL: https://www.irct.ir/user/profile). The
study protocol and reporting of results were adhered
to Consolidated Standards for Reporting Trials
(CONSORT).
Eligible patients were non-pregnant women and men
aged 18 years or older with definite diagnosis of COVID-
19 by Real Time RNA specific Reverse Transcriptase
Polymerase Chain Reaction (RT-PCR) or computed
tomography (CT) scan imaging (pneumonia), and oxy-
gen saturation of 94% or less. The findings of CT were
described as bilateral lung opacities and lobular and sub
segmental areas of consolidation [11]. Patients were en-
rolled into the study from hospitalized patients who
were admitted to the infectious diseases ward of Firooz-
gar teaching hospital. We considered a significance level
of 0.05 and 80% power to detect a moderate difference
(Standardized difference < 0.05) of hospitalization dur-
ation across two groups. Based on these criteria, the
sample size was calculated as 50 per group [12].
Patients gave written informed consent according to
regulations of ethics committee. We excluded partici-
pants who had a history of allergy to ARB class of drugs,
abnormal liver or renal function, abnormal blood coagu-
lation, prior use of ARB, women who were nursing or
were pregnant, and patients with severe heart disease.
Intervention
Participants were assigned to the intervention or control
groups using blocked randomization method. Envelopes
were prepared for unmasking randomization and alloca-
tion concealment. The random allocation procedure was
performed by an independent staff of the hospital in
which the RCT was run. The project manager and other
colleagues of current study enrolled and assigned partici-
pants to the interventions.
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In this trial patients with diagnosis of COVID-19 re-
ceived either hydroxychloroquine (400mg on first day)
followed by 400mg KALETRA (Lopinavir/ritonavir) BD
or Hydroxychloroquine (400mg BD on first day) followed
by ARB (200mg TDS) 7 to 14 days based on the severity
of disease. The capsule of ARB (100mg) was used in this
trial.
Patients monitored daily for adverse events, vital
signs, and changing of signs and symptoms. The
current trial was monitored by research branch of the
Food and Drug administration organization of Iran.
Outcome measures
The research objective of this study was the assessment of
potential superiority of ARB compared to KALETRA on
management of patients with COVID-19. The primary
outcome was duration of hospitalization and clinical im-
provement 7 days after admission. The criteria of im-
provement were relief of cough, dyspnea, and fever. Time
to relieving fever was also assessed across the two groups.
The secondary outcomes were death during the 30
days of treatment, duration of hospitalization, changing
laboratory tests during 7 days, changing of CT findings
after 30 days, and the need for invasive mechanical
ventilation.
We documented the age, gender, job, education status,
underlying disease (history of diabetes, ischemic heart
disease, hypertension, asthma,) and smoking status, as
demographic variables. Fever, cough, dyspnea, nausea
and vomiting, diarrhea, fatigue and weakness, loss of
appetite, and taste were also documented at the first day
of admission. The saturation of peripheral oxygen, C-
reactive protein (CRP), complete blood cell count (CBC),
erythrocyte sedimentation rate (ESR), aspartate trans-
aminase (AST), alanine aminotransferase (ALT), white
blood cell count (WBC), lymphocyte and neutrophil
count, neutrophil lymphocyte ratio, total bilirubin, blood
Na and K, creatinine and thyroid stimulating hormone
(TSH) were measured at the first day of admission and
7 days after. The CT scan and chest X-ray were taken at
the first day of admission and 30 days after. The PCR
test was taken at admission and the time of discharge.
We considered the following criteria for discharge
from hospital: Resolution of fever at least for 72 h and
decreasing trend in LDH and CRP and lymphocytosis
significant and having normal saturation of peripheral
oxygen.
We categorized the patients to three groups based on
severity of disease according to the CT scan and chest
X-ray findings. Mild, moderate and severe categories
were defined as involvement of base, less and more than
50% of the lung field respectively in CXR and CT scan.
Statistical analysis
Data analysis was carried out using SPSS version 24 soft-
ware (SPSS Inc., IL, and USA). The normality of data
Fig. 1 Consolidated standards of reporting trials (CONSORT) flow diagram
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was evaluated using Kolmogorov–Smirnov (KS) test.
Descriptive statistics including mean, frequency, and
standard deviation (SD) were calculated for all numeric
variables and expressed as mean ± SD. Chi-square test
was used to compare the qualitative variables across two
groups. For normally distributed variables, independent
sample and paired t-test were used across groups and
before-after analysis, respectively. We also used one way
Analysis of Variance (ANOVA) to assess numeric vari-
ables across groups more than two category. Correlation
analysis was used to evaluate the association between
numeric variables. The B regression coefficients, with
95% confidence intervals (CI), were obtained using
multiple linear regression analysis to assess the covari-
ates associated with duration of hospitalization adjusted.
All analyses were performed two-sided and significant
level was considered at 0.05.
Results
Of 104 recruited patients with COVID-19 admitted to
the hospital between 20 April and 18 June 2020, four
subjects were excluded due to contraindication of ARB
use. The remaining one hundred patients who fulfilled
inclusion criteria were assigned to the study and ran-
domized to hydroxychloroquine plus KALETRA or
hydroxychloroquine plus ARB. We did not have any lost
to follow-up; therefore 50 patients per group were
entered to final analysis (Fig. 1). The numeric data was
adhered to normal distribution using KS test (P < 0.05).
Table 1 illustrates the demographic characteristics of
the patients. The mean age of the patients was 56.6
(17.8) years and 56.2 (14.8) years in ARB and KALETRA
groups, respectively. Majority of patients were male
across two groups (66 and 54%). The percent of smokers
in ARB group was significantly higher than KALETRA
group (P = 0.01). About 40% of subjects reported history
of contact with a patient with COVID-19 during 2 weeks
before admission.
In Table 2, clinical characteristics of the patients is
shown. According to the signs and symptoms, patients
in ARB group had weakness and headache more than
the other group (70 and 26% versus 52 and 8%, respect-
ively). About 6.7% of patients in KALETRA arm needed
admission to Intensive Care Unit (ICU) versus 18.6% of
ARB group. The duration of hospitalization in ARB
group was significantly less than KALETRA arm (7.2
Table 1 Demographic Characteristics of the Patients by Treatment Groups
Characteristicsa All patients (n = 100) Arbidol group (n = 50) KALETRA group (n = 50)
Age, years (SD)b 56.4 (16.3) 56.6 (17.8) 56.2 (14.8)
Sex, n (%) 100 (100) 50 (100) 50 (100)
Male, n (%) 60 (60) 33 (66) 27 (54)
Female, n (%) 40 (40) 17 (34) 23 (46)
Marital status, n (%) 100 (100) 50 (100) 50 (100)
Single, n (%) 39 (39) 19 (38) 20 (40)
Married, n (%) 61 (61) 31 (62) 30 (60)
Job, n (%) 90 (100) 44 (100) 46 (100)
Hospital staff, n (%) 5 (5.5) 1 (2.3) 4 (8.7)
Self-employment, n (%) 32 (35.5) 16 (36.4) 16 (34.8)
Housekeeper, n (%) 35 (38.9) 15 (34.1) 20 (43.5)
Worker, n (%) 5 (5.6) 4 (9.1) 1 (2.2)
Employee, n (%) 13 (14.4) 8 (18.2) 5 (10.9)
Smoker, n (%) 15 (15) 12 (24) 3 (6)
Cigarette per day, n (SD) 12.2 (11.9) 13.5 (12.4) 5 (4.2)
Smoking duration, years (SD) 14.6 (8.2) 14.5 (8.6) 15 (7)
Comorbidities, n (%) 72 (72) 39 (78) 33 (66)
Hypertension, n (%) 39 (39) 22 (44) 17 (34)
Diabetes, n (%) 28 (28) 15 (30) 13 (26)
Coronary heart disease, n (%) 9 (9) 7 (14) 2 (4)
Asthma, n (%) 2 (2) 2 (4) 0 (0)
Chronic kidney disease, n (%) 2 (2) 1 (2) 1 (2)
Other diseases, n (%) 38 (38) 22 (44) 16 (32)
aData is presented as mean (standard deviation), n (%) or n (SD); bAbbreviation: SD standard deviation
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Table 2 Clinical Characteristics of the Patients by Treatment Groups
Characteristics All patients (n = 100) Arbidol group (n = 50) KALETRA group (n = 50) P Value
Signs and Symptoms, n (%)
Fever 46 (46) 19 (38) 27 (54) 0.1
Cough 80 (80) 41 (82) 39 (78) 0.6
Shortness of breath 66 (66) 33 (66) 33 (66) 0.99
Weakness 61 (61) 35 (70) 26 (52) 0.6
Anosmia 10 (10) 6 (12) 4 (8) 0.5
Diarrhea 15 (15) 12 (24) 3 (6) 0.01
Nausea and vomiting 26 (26) 11 (22) 15 (30) 0.3
Myalgia 45 (45) 20 (40) 25 (50) 0.3
Headache 17 (17) 13 (26) 4 (8) 0.01
Others 50 (50) 18 (36) 32 (64) 0.005
Hospitalization location, n (%) 88 (100) 43 (100) 45 (100) 0.09
ICU, n (%) 43 (48.8) 8 (18.6) 3 (6.7)
Ward, n (%) 45 (51.1) 35 (81.4) 42 (93.3)
Hospitalization duration, days (SD) 8.4 (5.1) 7.2 (4.7) 9.6 (5.2) 0.02
Time to stop fever, days (SD) 2.9 (1.3) 2.7 (1.1) 3.1 (1.4) 0.2
Illness severity, n (%) 0.9
Mild 19 (19) 9 (18) 10 (20)
Moderate 58 (58) 29 (58) 29 (58)
Severe 23 (23) 12 (24) 11 (22)
CT scan in beginning, n (%) 100 (100) 50 (100) 50 (100) 0.9
Involvement type, n (%)
Mild 11 (11) 5 (10) 6 (12)
Moderate 66 (66) 33 (66) 33 (66)
severe 23 (23) 12 (24) 11 (22)
CT scan in 30th day, n (%) 97 (100) 49 (100) 48 (100) 0.004
Involvement type, n (%)
Mild 63 (64.9) 38 (80.9) 25 (53.2)
Moderate 31 (31.9) 9 (19.1) 22 (46.8)
severe 0 (0) 0 (0) 0
CXR in beginning, n (%) 100 (100) 50 (100) 50 (100) 0.3
Involvement type, n (%)
Mild 25 (25) 11 (22) 14 (28)
Moderate 66 (66) 36 (72) 30 (60)
severe 9 (9) 3 (6) 6 (12)
CXR in 30th day, n (%) 97 (100) 49 (100) 48 (100) < 0.001
Involvement type, n (%)
Mild 75 (77.3) 44 (95.7) 31 (67.4)
Moderate 17 (17.5) 2 (4.3) 15 (32.6)
severe 0 (0) 0 (0) 0 (0)
Intubation, n (%) 5 (5) 3 (6) 2 (4) 0.6
Mechanical Ventilation, n (%) 5 (5) 3 (6) 2 (4) 0.6
Mortality, n (%) 3 (3) 1 (2) 2 (4) 0.5
Medication side effect, n (%) 15 (100) 3 (100) 12 (100) 0.1
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versus 9.6 days; P = 0.02). The severity of disease based
on CT scan and chest X-ray findings were significantly
different after 30 days of admission despite of almost
similar severity at the day of admission. The mild finding
based on CT scan was about 81% versus 53.2% in ARB
and KALETRA groups, respectively. This result based on
chest X-ray was 96% versus 67% in ARB and KALETRA
arms, respectively.
Time to relief fever was similar across two groups (2.7
versus 3.1 days in ARB and KALETRA arms, respect-
ively). Although the time for ARB group was less than
KALETRA, but the difference was not statistically sig-
nificant. The side effects of both drugs were not consid-
erable. The most common adverse event was nausea and
vomiting specially in KALETRA group. Patients in the
ARB group experienced lower rates of nausea/vomiting
compared to the KALETRA group. Among patients with
nausea/vomiting about 33% versus 58% were belong to
ARB and KALETRA respectively. Although this differ-
ence was not statistically significant. Furthermore, no
evidence of dizziness was reported in the ARB group,
while all patients with dizziness were from in KALETRA
group. Compared to ARB, patients who received KALE
TRA had slightly higher ALT levels after 7 days of
admission (32.2 ± 14.5 vs. 28.3 ± 15.6 U/L, respectively).
The intubation and need to mechanical ventilation
rates were not different across two groups. Out of
100 patients, there were three deaths totally. One
death occurred in ARB and two deaths in KALETRA
group (Table 2).
According to laboratory findings, the conversion of
CRP test was almost similar after 7 days of admission.
Although, the two plus CRP was higher in patients in
KALETRA group vs. ARB group (35%% versus 20%) but
statistically insignificant (Table 3).
The PCR of 50% of patients at the time of admission
was positive. This proportion at the time of discharge
from hospital was about 38% totally. The positive PCR
rate at the time of discharge in KALETRA and ARB
group was 23 and 14%, respectively (Table 3).
Peripheral oxygen saturation rate was significantly dif-
ferent after 7 days of admission across two groups (94%
versus 92% in ARB and KALETRA groups, respectively)
(P = 0.02). Also WBC and neutrophil counts, ESR and
blood K were significantly different after 7 days of
admission between ARB and KALETRA arms despite of
similar values at the time of admission. Totally apart
from comparative groups, peripheral oxygen saturation,
ESR, WBC, neutrophil and lymphocyte counts, neutro-
phil to lymphocyte ratio, and blood Na were significantly
different at the time of admission and 7 days after sig-
nificantly (P < 0.001) (Table 3).
Patients who had history of ischemic heart disease
(IHD) were hospitalized more than the patients with-
out this history (11.3 (4.9) versus 8.1 (5.0) days). This
difference was statistically significant at less than 0.1
(P = 0.09) partially. The duration of hospitalization for
patients with diabetes mellitus (DM) was also more
than patients without this disease (10 (4.0) versus 7.8
(5.3) days). This difference was statistically significant
(P = 0.04). Based on CT scan findings at the time of
admission, the patients who categorized in severe
group hospitalized more days than the mild group.
(12 (5.4) versus 2 (2.0) days) (P < 0.01). Patients with
more peripheral saturation of oxygen had a signifi-
cantly shorter duration of hospitalization than the pa-
tients with lower saturation (r = 0.50; P = 0.01). High
WBC count at the time of admission was correlated
with higher duration of hospitalization (r = 0.27; P =
0.007). The Na level and lymphocytosis at the time of
admission were correlated with duration of
hospitalization reversely (r = − 0.32; P = 0.01, r = − 0.15;
P = 0.05, respectively) (data was not shown). The la-
boratory data were not different based on severity of
disease at the time of admission, but WBC count was
higher in severe cases than mild and moderate cat-
egories (15 versus 8.8 and 8.1 × 109/L, respectively).
Based on multiple linear regression analysis, IHD, Na
level and oxygen saturation at the time of admission and
type of therapy were the independent adjusted variables
that determined the duration of hospitalization in pa-
tients with COVID-19. The lymphocytosis at the level of
0.06 probability value could be another determinant fac-
tor for duration of hospitalization (Table 4).
Discussion
Since COVID-19 was became a pandemic, a variety of
antiviral drugs have been investigated on patients with
COVID-19 [13]. Arbidol is a Russian antiviral drug
that seems to be effective against many viruses in-
cluding influenza A, B, and C, respiratory syncytial
virus (RSV), severe acute respiratory syndrome-related
Table 2 Clinical Characteristics of the Patients by Treatment Groups (Continued)
Characteristics All patients (n = 100) Arbidol group (n = 50) KALETRA group (n = 50) P Value
Nausea/vomiting, n (%) 8 (53.5) 1 (33.3) 7 (58.3)
Dizziness, n (%) 3 (20) 0 (0) 3 (25)
Others, n (%) 4 (26.7) 2 (66.7) 2 (16.7)
Note: Data are presented as mean (standard deviation) or n (%)
Abbreviation: ICU Intensive Care Unit, CT Computerized Tomography, CXR Chest X-ray, SD Standard Deviation
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Table 3 Laboratory findings of the Patients by Treatment groups
Laboratory findings All patients (n = 100) Arbidol group (n = 50) KALETRA group (n = 50) P Value
CRP Base, n (%) 100 (100) 50 (100) 50 (100) 0.6
0, n (%) 16 (16) 7 (14) 9 (18)
+, n (%) 29 (29) 15 (30) 14 (28)
++, n (%) 29 (29) 17 (34) 12 (24)
+++, n (%) 26 (26) 11 (22) 15 (30)
CRP 7th day, n (%) 99 (100) 50 (100) 49 (100) 0.2
0, n (%) 33 (33.3) 17 (34) 16 (32.7)
+, n (%) 38 (38.3) 23 (46) 15 (30.6)
++, n (%) 27 (27.2) 10 (20) 17 (34.7)
+++, n (%) 1 (2) 0 (0) 1 (2)
PCR Base, n (%) 100 (100) 50 (50) 50 (50) 0.8
Positive, n (%) 51 (51) 25 (50) 26 (52)
PCR Discharge, n (%) 97 (100) 49 (100) 48 (100) 0.2
Positive, n (%) 18 (38.2) 7 (14.3) 11 (22.9)
Oxygen Saturation, % (SD) < 0.001
In admission 84.9 (8) 85.5 (8.4) 84.3 (7.7) 0.4
7th day 93 (4.2) 93.9 (3.1) 92 (4.8) 0.02
Erythrocyte Sedimentation Rate, mm/h (SD) < 0.001
In admission 40 (19.9) 38.7 (19.7) 41.4 (20.3) 0.5
7th day 27.8 (17.4) 23.3 (15.5) 32.2 (18.2) 0.01
White-cell count, ×109/L (SD) < 0.001
In admission 10.1 (4.9) 10.5 (4.1) 9.8 (5.5) 0.4
7th day 6.7 (2.2) 6.2 (1.7) 7.2 (2.5) 0.03
Lymphocyte count, × 109/L (SD) < 0.001
In admission 20.4 (8.7) 20.3 (8.7) 20.4 (8.9) 0.9
7th day 26.3 (10.6) 24.7 (8.9) 27.9 (12) 0.1
Neutrophil count, ×109/L (SD) < 0.001
In admission 73.8 (11.2) 74.6 (9.7) 73 (12.6) 0.4
7th day 65.9 (13.2) 69.1 (11.2) 62.7 (14.4) 0.01
Neutrophil/ Lymphocyte ratio (SD) < 0.001
In admission 4.7 (3.3) 4.8 (3.7) 4.6 (2.8) 0.7
7th day 3.4 (3.7) 3.7 (4.3) 3.2 (2.9) 0.4
AST, IU/L (SD) 0.9
In admission 34.3 (19.9) 33.8 (23.7) 34.7 (15.5) 0.8
7th day 32.5 (15.2) 31.1 (15.9) 33.8 (14.4) 0.3
ALT, IU/L (SD) 0.1
In admission 28.8 (16.4) 28.1 (18.2) 29.5 (14.6) 0.6
7th day 30.2 (15.1) 28.3 (15.6) 32.2 (14.5) 0.2
Total Bilirubin, mg/dL (SD) 0.3
In admission 0.9 (0.5) 1 (0.5) 0.9 (0.4) 0.3
7th day 1 (0.4) 1 (0.5) 1 (0.4) 0.8
Serum Creatinine, μmol/L (SD) 0.01
In admission 1 (0.6) 1.1 (0.8) 0.9 (0.2) 0.1
7th day 0.9 (0.4) 1 (0.6) 0.9 (0.2) 0.1
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coronavirus (SARS-CoV), adenovirus, parainfluenza,
poliovirus, rhinovirus, coxsackievirus, Zika virus,
hepatitis B and C viruses [14–16]. It has been demon-
strated that ARB has a dual effect on cell attachment
and replication, and thus a broad-spectrum effect on
viruses [8, 17], so it is administered for post-exposure
prophylaxis and treatment [18]. Therefore, ARB is
considered to be one of the antiviral drugs that can
be effective in the treatment of COVID-19 patients.
In the present randomized controlled trial, we com-
pared the efficacy and safety of antiviral ARB to
KALETRA in COVID-19 patients and showed several
benefits in the ARB group compared to KALETRA
group. During the study, 100 patients were assigned,
50 patients were assigned to receive ARB and 50 to
receive KALETRA.
We reported that nausea/vomiting was the most com-
mon side effect among the study participants. Data also
showed that both drugs had no seriously side effects.
Similarly, reports found no life-threatening adverse
events in ARB and KALETRA groups [19, 20], except Li
et al. study, which presented an old male patient with a
history of diabetes mellitus and hypertension in the
KALETRA group, who experienced severe diarrhea on
day three of initiating treatment [19].
COVID-19 Patients treated with KALETRA are more
likely to show higher WBC counts and CRP serum levels
than those who received ARB. Regarding WBC differen-
tial, neutrophil counts seem to be higher, while lympho-
cyte counts appear to be lower in KALETRA-treated
patients than in ARB [20]. In the present report, we ob-
served that KALETRA, compared to ARB, was signifi-
cantly associated with higher counts of WBC and ESR
serum levels after 7 days of admission. On the other
hand, although we found that patients in the KALETRA
group had higher proportions of CRP ≥ 2+ than the ARB
group 7 days after admission, there was no significant
difference between them. After 7 days of admission, neu-
trophil counts were significantly lower in the KALETRA
group than in ARB. However, different findings between
reports could be attributed to differences in the design
of studies, treatment regimens, and sample sizes.
We have shown that slightly higher proportions of
patients in the ARB group had severe clinical status
Table 3 Laboratory findings of the Patients by Treatment groups (Continued)
Laboratory findings All patients (n = 100) Arbidol group (n = 50) KALETRA group (n = 50) P Value
Blood Sodium, mEq/L (SD) < 0.001
In admission 136.3 (3.7) 136.1 (3.8) 136.4 (3.6) 0.7
7th day 140.5 (3) 140.7 (2.9) 140.3 (3.1) 0.5
Blood Potassium, mmol/L (SD) 0.08
In admission 3.9 (0.5) 3.9 (0.5) 3.9 (0.5) 0.9
7th day 4 (0.5) 3.9 (0.4) 4.2 (0.5) 0.001
TSH, mIU/L (SD) 0.3
In admission 4.2 (1.8) 4.4 (1.9) 4.1 (1.7) 0.3
7th day 4.1 (1.8) 4.2 (1.9) 4 (1.7) 0.5
Note: Data are presented as mean (standard deviation) or n (%)
Abbreviation: CRP C-Reactive Protein, PCR Polymerase Chain Reaction, SD Standard Deviation, U/L Units/Liter, mm/h Millimeter/Hour, SGOT Serum Glutamic
Oxaloacetic Transaminase, SGPT Serum Glutamic-Pyruvic Transaminase, mg/dl Milligrams per Deciliter, TSH Thyroid Stimulating Hormone
*P-values indicate differences between patients in the Arbidol and the KALETRA groups and between in hospital and 7th day laboratory findings. P < 0.05 was
considered statistically significant





95.0% Confidence Interval for B
Lower Bound Upper Bound
(Constant) 73.438 15.261 4.812 .000 43.129 103.747
Arbidol group 2.596 .837 3.102 .003 .934 4.258
Without IHDb −3.842 1.482 −2.593 .011 −6.786 −.899
Without DMb .122 1.005 .121 .904 −1.874 2.118
WBC .113 .093 1.214 .228 −.072 .298
Oxygen saturation −.238 .061 −3.900 .000 −.359 −.117
Lymphocytosis −.089 .048 −1.865 .065 −.183 .006
Na level −.300 .112 −2.670 .009 −.523 −.077
aThe White blood cell count (WBC), lymphocytosis, Na level and Oxygen saturation are for the time of admission
bIschemic heart disease; Diabetes Mellitus
Nojomi et al. BMC Infectious Diseases          (2020) 20:954 Page 8 of 10
compared to the KALETRA group (24% vs. 22%,
respectively), while it did not significantly differ be-
tween groups. However, ARB is considered to minimize
the rates of worsening of the clinical condition. It has
been reported that a lower prevalence of COVID-19 pa-
tients who received ARB (8.6%) deteriorated to severe
clinical status compared to patients who received KALE
TRA (23.5%) during the hospitalization, but no signifi-
cant difference between the two groups of treatment
was found [19].
Although all of the patients in both groups had similar
severity on admission, 18.6% of patients in ARB group
were candidates for referring to the intensive care unit
(ICU) during admission versus 81% of patients in KALE
TRA group. Patients in the ARB group spent a shorter
duration of hospitalization (7.2 days) compared to KALE
TRA group (9.6 days, p-value = 0.02). Furthermore, 81%
of patients in ARB group had mild involvement on the
chest CT scan after 30 days of admission compared to
53% in KALETRA group (p-value = 0.004). Noteworthy,
we noticed several demographic, clinical, and laboratory
determinants of duration of hospitalization in COVID-
19 patients, including IHD, oxygen saturation on admis-
sion, treatment with ARB, plasma Na levels, and lym-
phocytosis with a probability value of 0.06. In this
regard, two cohort studies from Wuhan, China noted
that COVID-19 patients aged ≥80 years and with lym-
phopenia (< 1.1 × 109/L) had a longer duration of
hospitalization [21, 22].
Collectively, our findings indicate a lower proportion
of ICU admissions, a shorter length of hospital stay, and
a higher percentage of mild chest CT involvement after
30 days of admission among the COVID-19 patients
who were treated with ARB compared to KALETRA,
representing that ARB may be superior to KALETRA in
the management of COVID-19 patients. Although, to
date, no vaccines or antiviral drugs are approved for the
treatment of COVID-19, “National Health Commission
and National Administration of Traditional Chinese
Medicine” have recently recommended KALETRA com-
bined with ARB and reported its antiviral effects [23].
However, to our knowledge, limited documents are
evaluating the efficacy and safety of ARB on COVID-19
patients. Consistent with our study, a retrospective study
from China compared the efficacy and safety of KALE
TRA to ARB in COVID-19 patients [20]. They detected
no viral load in the ARB group, while a viral load of
44.1% was found in the KALETRA group, concluded
that ARB monotherapy might be more effective than
KALETRA for COVID-19 treatment. Similarly, another
retrospective study found that ARB, combined with
KALETRA, compared to KALETRA alone, would im-
prove the viral clearance and chest CT scans [24]. A co-
hort study of 504 hospitalized COVID-19 patients with
mixed illness severities presented that ARB significantly
reduced mortality (OR = 0.183, 95% CI = 0.075–0.446),
and it was more likely to absorb lesions on chest CT
scan [25]. However, a randomized controlled trial by Li
et al. and a retrospective study by Chen et al. suggested
that neither the COVID-19 symptoms or chest CT in-
volvement, nor the time to SARS-CoV-2 PCR negative
in respiratory specimens was improved/decreased in pa-
tients who received KALETRA and ARB [19, 26]. Des-
pite the small sample size in Li et al. study [19], they did
not recruit severely or critically ill cases. Additionally,
different from Li et al. [19], we gave KALETRA and
ARB in combination with hydroxychloroquine to each
group. Nevertheless, we believe that our findings are
likely to help physicians develop appropriate treatment
strategies among evolving evidence for COVID-19
management.
Conclusion
To the best of our knowledge, the present randomized
controlled trial is the first study from Iran, highlighting
the benefits of ARB monotherapy for the treatment of
hospitalized COVID-19 patients. We have shown that
ARB, compared to KALETRA, significantly contributes
to clinical and laboratory improvements, including per-
ipheral oxygen saturation, requiring ICU admissions,
duration of hospitalization, chest CT involvements,
WBC, and ESR.
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